Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Roche price target lowered to CHF 350 from CHF 370 at Credit Suisse » 14:50
05/19/22
05/19
14:50
05/19/22
14:50
RHHBY

Roche

$40.34 /

-0.03 (-0.07%)

Credit Suisse analyst…

Credit Suisse analyst Trung Huynh lowered the firm's price target on Roche to CHF 350 from CHF 370 and keeps a Neutral rating on the shares.

ShowHide Related Items >><<
RHHBY Roche
$40.34 /

-0.03 (-0.07%)

RHHBY Roche
$40.34 /

-0.03 (-0.07%)

05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
05/12/22 Morgan Stanley
Roche price target lowered to CHF 370 from CHF 395 at Morgan Stanley
05/11/22 Piper Sandler
iTeos Therapeutics price target lowered to $34 from $42 at Piper Sandler
05/11/22 Wedbush
Arcus Biosciences price target lowered to $42 from $67 at Wedbush
RHHBY Roche
$40.34 /

-0.03 (-0.07%)

RHHBY Roche
$40.34 /

-0.03 (-0.07%)

RHHBY Roche
$40.34 /

-0.03 (-0.07%)

Wednesday
Hot Stocks
Sorrento Therapeutics appoints Tammy Reilly to board of directors » 09:04
05/18/22
05/18
09:04
05/18/22
09:04
SRNE

Sorrento Therapeutics

$1.59 /

+0.14 (+9.69%)

, RHHBY

Roche

$40.37 /

+0.25 (+0.62%)

Sorrento Therapeutics…

Sorrento Therapeutics announced the appointment of Tammy Reilly, to Sorrento's board of directors. Ms. Reilly is the managing partner of a life sciences advisory company, TRDx LLC, an independent firm that she founded 15 years ago to advise life science companies on life cycle management and business development solutions, which includes advice on mergers and acquisitions and strategic and capital markets transactions. Reilly also served in various roles at Roche Laboratories for over 14 years, including sales and marketing leadership positions and most recently in 2005 as Executive Vice President for Oncology and Dermatology at Roche.

ShowHide Related Items >><<
SRNE Sorrento Therapeutics
$1.59 /

+0.14 (+9.69%)

RHHBY Roche
$40.37 /

+0.25 (+0.62%)

SRNE Sorrento Therapeutics
$1.59 /

+0.14 (+9.69%)

03/25/22 H.C. Wainwright
Sorrento Therapeutics price target lowered to $20 from $26 at H.C. Wainwright
12/28/21 H.C. Wainwright
H.C. Wainwright reiterates $26 target on Sorrento after Covistix news
08/09/21 H.C. Wainwright
Sorrento Therapeutics price target lowered to $26 from $30 at H.C. Wainwright
RHHBY Roche
$40.37 /

+0.25 (+0.62%)

05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
05/12/22 Morgan Stanley
Roche price target lowered to CHF 370 from CHF 395 at Morgan Stanley
05/11/22 Piper Sandler
iTeos Therapeutics price target lowered to $34 from $42 at Piper Sandler
05/11/22 Wedbush
Arcus Biosciences price target lowered to $42 from $67 at Wedbush
RHHBY Roche
$40.37 /

+0.25 (+0.62%)

RHHBY Roche
$40.37 /

+0.25 (+0.62%)

RHHBY Roche
$40.37 /

+0.25 (+0.62%)

SRNE Sorrento Therapeutics
$1.59 /

+0.14 (+9.69%)

Monday
Conference/Events
Roche to hold a virtual event » 08:50
05/16/22
05/16
08:50
05/16/22
08:50
RHHBY

Roche

$39.75 /

+0.21 (+0.53%)

Virtual ESG Event: Access…

Virtual ESG Event: Access to Healthcare to be held on May 16 at 9 am. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$39.75 /

+0.21 (+0.53%)

RHHBY Roche
$39.75 /

+0.21 (+0.53%)

05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
05/12/22 Morgan Stanley
Roche price target lowered to CHF 370 from CHF 395 at Morgan Stanley
05/11/22 Piper Sandler
iTeos Therapeutics price target lowered to $34 from $42 at Piper Sandler
05/11/22 Wedbush
Arcus Biosciences price target lowered to $42 from $67 at Wedbush
RHHBY Roche
$39.75 /

+0.21 (+0.53%)

RHHBY Roche
$39.75 /

+0.21 (+0.53%)

RHHBY Roche
$39.75 /

+0.21 (+0.53%)

Conference/Events
Roche to hold a virtual event » 04:55
05/16/22
05/16
04:55
05/16/22
04:55
RHHBY

Roche

$39.75 /

+0.21 (+0.53%)

Virtual ESG Event: Access…

Virtual ESG Event: Access to Healthcare to be held on May 16 at 9 am. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$39.75 /

+0.21 (+0.53%)

RHHBY Roche
$39.75 /

+0.21 (+0.53%)

05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
05/12/22 Morgan Stanley
Roche price target lowered to CHF 370 from CHF 395 at Morgan Stanley
05/11/22 Piper Sandler
iTeos Therapeutics price target lowered to $34 from $42 at Piper Sandler
05/11/22 Wedbush
Arcus Biosciences price target lowered to $42 from $67 at Wedbush
RHHBY Roche
$39.75 /

+0.21 (+0.53%)

RHHBY Roche
$39.75 /

+0.21 (+0.53%)

RHHBY Roche
$39.75 /

+0.21 (+0.53%)

Conference/Events
Roche to hold a virtual event » 00:09
05/16/22
05/16
00:09
05/16/22
00:09
RHHBY

Roche

$39.75 /

+0.21 (+0.53%)

Virtual ESG Event: Access…

Virtual ESG Event: Access to Healthcare to be held on May 16 at 9 am. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$39.75 /

+0.21 (+0.53%)

RHHBY Roche
$39.75 /

+0.21 (+0.53%)

05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
05/12/22 Morgan Stanley
Roche price target lowered to CHF 370 from CHF 395 at Morgan Stanley
05/11/22 Piper Sandler
iTeos Therapeutics price target lowered to $34 from $42 at Piper Sandler
05/11/22 Wedbush
Arcus Biosciences price target lowered to $42 from $67 at Wedbush
RHHBY Roche
$39.75 /

+0.21 (+0.53%)

RHHBY Roche
$39.75 /

+0.21 (+0.53%)

RHHBY Roche
$39.75 /

+0.21 (+0.53%)

Over a week ago
Downgrade
Roche downgraded to Hold from Buy at Jefferies » 06:03
05/13/22
05/13
06:03
05/13/22
06:03
RHHBY

Roche

$39.54 /

-1.02 (-2.51%)

, NVS

Novartis

$85.38 /

+1.36 (+1.62%)

, GSK

GlaxoSmithKline

$42.48 /

-0.075 (-0.18%)

Jefferies analyst Peter…

Jefferies analyst Peter Welford downgraded Roche (RHHBY) to Hold from Buy with a price target of CHF 360, down from CHF 430. The analyst says oncology pipelines setbacks for tiragolumab and giredestrant has "many growing wary" into the gantenerumab binary Alzheimer's readout in Q4. He prefers GlaxoSmithKline (GSK) in the near term on the company's consumer spin value creation as well as Novartis (NVS) for Swiss yield and value.

ShowHide Related Items >><<
RHHBY Roche
$39.54 /

-1.02 (-2.51%)

NVS Novartis
$85.38 /

+1.36 (+1.62%)

GSK GlaxoSmithKline
$42.48 /

-0.075 (-0.18%)

RHHBY Roche
$39.54 /

-1.02 (-2.51%)

05/12/22 Morgan Stanley
Roche price target lowered to CHF 370 from CHF 395 at Morgan Stanley
05/11/22 Piper Sandler
iTeos Therapeutics price target lowered to $34 from $42 at Piper Sandler
05/11/22 Wedbush
Arcus Biosciences price target lowered to $42 from $67 at Wedbush
05/11/22 Deutsche Bank
Roche downgraded to Hold from Buy at Deutsche Bank
NVS Novartis
$85.38 /

+1.36 (+1.62%)

05/09/22 Wolfe Research
Novartis downgraded to Peer Perform from Outperform at Wolfe Research
05/06/22 Morgan Stanley
Novartis price target raised to CHF 94 from CHF 90 at Morgan Stanley
04/28/22 SVB Leerink
Molecular Partners price target lowered to $29 from $42 at SVB Leerink
04/27/22 Credit Suisse
Novartis price target raised to CHF 88 from CHF 85 at Credit Suisse
GSK GlaxoSmithKline
$42.48 /

-0.075 (-0.18%)

04/29/22 Barclays
GlaxoSmithKline price target raised to 1,800 GBp from 1,775 GBp at Barclays
04/28/22 JPMorgan
GlaxoSmithKline price target raised to 1,900 GBp from 1,740 GBp at JPMorgan
04/14/22 Barclays
GlaxoSmithKline price target raised to 1,775 GBp from 1,675 GBp at Barclays
04/14/22 Oppenheimer
Sierra Oncology downgraded to Perform from Outperform at Oppenheimer
RHHBY Roche
$39.54 /

-1.02 (-2.51%)

NVS Novartis
$85.38 /

+1.36 (+1.62%)

GSK GlaxoSmithKline
$42.48 /

-0.075 (-0.18%)

RHHBY Roche
$39.54 /

-1.02 (-2.51%)

NVS Novartis
$85.38 /

+1.36 (+1.62%)

GSK GlaxoSmithKline
$42.48 /

-0.075 (-0.18%)

RHHBY Roche
$39.54 /

-1.02 (-2.51%)

NVS Novartis
$85.38 /

+1.36 (+1.62%)

GSK GlaxoSmithKline
$42.48 /

-0.075 (-0.18%)

GSK GlaxoSmithKline
$42.48 /

-0.075 (-0.18%)

Recommendations
Roche price target lowered to CHF 370 from CHF 395 at Morgan Stanley » 15:39
05/12/22
05/12
15:39
05/12/22
15:39
RHHBY

Roche

$40.56 /

-4.06 (-9.10%)

Morgan Stanley analyst…

Morgan Stanley analyst Mark Purcell lowered the firm's price target on Roche to CHF 370 from CHF 395 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
RHHBY Roche
$40.56 /

-4.06 (-9.10%)

RHHBY Roche
$40.56 /

-4.06 (-9.10%)

05/11/22 Piper Sandler
iTeos Therapeutics price target lowered to $34 from $42 at Piper Sandler
05/11/22 Wedbush
Arcus Biosciences price target lowered to $42 from $67 at Wedbush
05/11/22 Deutsche Bank
Roche downgraded to Hold from Buy at Deutsche Bank
05/09/22 Wedbush
Wedbush downgrades Arvinas to Neutral, cuts price target to $43
RHHBY Roche
$40.56 /

-4.06 (-9.10%)

RHHBY Roche
$40.56 /

-4.06 (-9.10%)

RHHBY Roche
$40.56 /

-4.06 (-9.10%)

Recommendations
iTeos Therapeutics price target lowered to $34 from $42 at Piper Sandler » 10:20
05/11/22
05/11
10:20
05/11/22
10:20
ITOS

iTeos Therapeutics

$18.13 /

-7.505 (-29.28%)

, RHHBY

Roche

$44.62 /

+1.02 (+2.34%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond lowered the firm's price target on iTeos Therapeutics (ITOS) to $34 from $42 and keeps an Overweight rating on the shares. The anlayst sees a higher risk profile for iTeos after Roche's (RHHBY) anti-TIGIT antibody tiragolumab failed to show a benefit in non-small cell lung cancer. Given the direct read-through to EOS-448, investors must acknowledge this "much anticipated" new immuno-oncology class now has more risk, Raymond tells investors in a research note. On the "bright side," investors can take comfort in iTeos management's foresight in partnering the molecule to GSK for $625M up front providing cash runway into 2026, adds the analyst.

ShowHide Related Items >><<
RHHBY Roche
$44.62 /

+1.02 (+2.34%)

ITOS iTeos Therapeutics
$18.13 /

-7.505 (-29.28%)

ITOS iTeos Therapeutics
$18.13 /

-7.505 (-29.28%)

05/06/22 Wedbush
Unity Software, iTeos removed from Wedbush Best Ideas List
12/16/21 Wedbush
iTeos Therapeutics added to 'Best Ideas List' at Wedbush
12/13/21 H.C. Wainwright
iTeos Therapeutics price target raised to $54 from $37 at H.C. Wainwright
11/11/21 Piper Sandler
iTeos Therapeutics price target lowered to $42 from $50 at Piper Sandler
RHHBY Roche
$44.62 /

+1.02 (+2.34%)

05/11/22 Wedbush
Arcus Biosciences price target lowered to $42 from $67 at Wedbush
05/11/22 Deutsche Bank
Roche downgraded to Hold from Buy at Deutsche Bank
05/09/22 Wedbush
Wedbush downgrades Arvinas to Neutral, cuts price target to $43
05/03/22 Piper Sandler
Piper keeps Overweight rating on Ionis after Biogen's Spinraza beat
RHHBY Roche
$44.62 /

+1.02 (+2.34%)

RHHBY Roche
$44.62 /

+1.02 (+2.34%)

RHHBY Roche
$44.62 /

+1.02 (+2.34%)

Recommendations
Arcus Biosciences price target lowered to $42 from $67 at Wedbush » 07:42
05/11/22
05/11
07:42
05/11/22
07:42
RCUS

Arcus Biosciences

/

+

, RHHBY

Roche

$44.62 /

+1.02 (+2.34%)

Wedbush analyst Robert…

Wedbush analyst Robert Driscoll lowered the firm's price target on Arcus Biosciences (RCUS) to $42 from $67 and keeps an Outperform rating on the shares. The analyst notes Roche (RHHBY) reported that the Phase 3 SKYSCRAPER-01 study failed to meet the co-primary endpoint of PFS, which he believes casts a shadow on Arcus' mNSCLC programs given the similarity of study designs.

ShowHide Related Items >><<
RHHBY Roche
$44.62 /

+1.02 (+2.34%)

RCUS Arcus Biosciences
/

+

RCUS Arcus Biosciences
/

+

03/15/22 Citi
Arcus Biosciences price target lowered to $48 from $53 at Citi
02/25/22 Truist
Arcus Biosciences price target raised to $77 from $70 at Truist
01/13/22 Goldman Sachs
Arcus Biosciences price target lowered to $43 from $45 at Goldman Sachs
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
RHHBY Roche
$44.62 /

+1.02 (+2.34%)

05/11/22 Deutsche Bank
Roche downgraded to Hold from Buy at Deutsche Bank
05/09/22 Wedbush
Wedbush downgrades Arvinas to Neutral, cuts price target to $43
05/03/22 Piper Sandler
Piper keeps Overweight rating on Ionis after Biogen's Spinraza beat
04/26/22 Stifel
Arvinas price target lowered to $85 from $93 at Stifel
RHHBY Roche
$44.62 /

+1.02 (+2.34%)

RCUS Arcus Biosciences
/

+

RHHBY Roche
$44.62 /

+1.02 (+2.34%)

RHHBY Roche
$44.62 /

+1.02 (+2.34%)

RCUS Arcus Biosciences
/

+

Downgrade
Roche downgraded to Hold from Buy at Deutsche Bank » 05:57
05/11/22
05/11
05:57
05/11/22
05:57
RHHBY

Roche

$44.62 /

+1.02 (+2.34%)

Deutsche Bank analyst…

Deutsche Bank analyst Emmanuel Papadakis downgraded Roche to Hold from Buy with a CHF 350 price target after the Phase III SKYSCRAPER-01 study failed in lung cancer. "It is indeed back to the drawing board," Papadakis tells investors in a research note.

ShowHide Related Items >><<
RHHBY Roche
$44.62 /

+1.02 (+2.34%)

RHHBY Roche
$44.62 /

+1.02 (+2.34%)

05/09/22 Wedbush
Wedbush downgrades Arvinas to Neutral, cuts price target to $43
05/03/22 Piper Sandler
Piper keeps Overweight rating on Ionis after Biogen's Spinraza beat
04/26/22 Stifel
Arvinas price target lowered to $85 from $93 at Stifel
04/25/22 H.C. Wainwright
Lineage Cell's PNC program 'an expected and logical move,' says H.C. Wainwright
RHHBY Roche
$44.62 /

+1.02 (+2.34%)

RHHBY Roche
$44.62 /

+1.02 (+2.34%)

RHHBY Roche
$44.62 /

+1.02 (+2.34%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.